- Joined
- Feb 28, 2010
- Messages
- 1,187
Am J Gastroenterol 2010.
When patients with inflammatory bowel disease (IBD) in remission have irritable bowel symptoms, the cause is more likely to be low-grade inflammation rather than true irritable bowel syndrome (IBS), according to a new study.
To identify the cause of IBS-like symptoms in IBD patients, the researchers measured fecal calprotectin, a marker for colonic inflammation. Calprotectin levels were higher in IBD patients with IBS-like symptoms than in other IBD patients and control groups.
"This study provides convincing evidence that (IBS) symptoms reflect ongoing IBD activity," the researchers write in their paper, which appeared online April 13 in the American Journal of Gastroenterology.
In the two-part study, Dr. Fergus Shanahan from Cork University Hospital, Ireland, and colleagues first evaluated 62 patients with Crohn's disease and 44 with ulcerative colitis. They defined remission of each condition according to the appropriate clinical criteria, activity indices, and C-reactive protein levels.
On that basis, all of their subjects were in remission. Even so, 37 Crohn's disease patients (59.7%) and 17 ulcerative colitis patients (38.6%) met Rome II criteria for IBS.
To evaluate the likely cause of IBS symptoms, the researchers stratified patients according to IBD etiology and IBS symptom status. They also analyzed two control groups: 34 healthy women without gastrointestinal symptoms and 41 women with confirmed IBS.
Fecal calprotectin levels were higher in Crohn's patients with IBS symptoms than in those without (415 vs. 175 mg/kg, p=0.009). The levels were similarly higher in ulcerative colitis patients with IBS symptoms compared to those without (591 vs. 230 mg/kg, p = 0.004).
Calprotectin levels in the inflammatory bowel disease patients - regardless of IBS symptom status - "greatly exceeded" levels in controls, the authors said.
"This study confirms the validity of calprotectin in distinguishing IBD from both IBS and control subjects and again illustrates that calprotectin levels are within the normal range in IBS," the researchers write.
While some IBD patients might technically qualify for an IBS diagnosis as well, the presence of IBS-like symptoms should always be interpreted as subclinical activity of their primary disease, according to the investigators.
Their conclusion: "Bottom line, IBD is IBD unless proven otherwise!"
When patients with inflammatory bowel disease (IBD) in remission have irritable bowel symptoms, the cause is more likely to be low-grade inflammation rather than true irritable bowel syndrome (IBS), according to a new study.
To identify the cause of IBS-like symptoms in IBD patients, the researchers measured fecal calprotectin, a marker for colonic inflammation. Calprotectin levels were higher in IBD patients with IBS-like symptoms than in other IBD patients and control groups.
"This study provides convincing evidence that (IBS) symptoms reflect ongoing IBD activity," the researchers write in their paper, which appeared online April 13 in the American Journal of Gastroenterology.
In the two-part study, Dr. Fergus Shanahan from Cork University Hospital, Ireland, and colleagues first evaluated 62 patients with Crohn's disease and 44 with ulcerative colitis. They defined remission of each condition according to the appropriate clinical criteria, activity indices, and C-reactive protein levels.
On that basis, all of their subjects were in remission. Even so, 37 Crohn's disease patients (59.7%) and 17 ulcerative colitis patients (38.6%) met Rome II criteria for IBS.
To evaluate the likely cause of IBS symptoms, the researchers stratified patients according to IBD etiology and IBS symptom status. They also analyzed two control groups: 34 healthy women without gastrointestinal symptoms and 41 women with confirmed IBS.
Fecal calprotectin levels were higher in Crohn's patients with IBS symptoms than in those without (415 vs. 175 mg/kg, p=0.009). The levels were similarly higher in ulcerative colitis patients with IBS symptoms compared to those without (591 vs. 230 mg/kg, p = 0.004).
Calprotectin levels in the inflammatory bowel disease patients - regardless of IBS symptom status - "greatly exceeded" levels in controls, the authors said.
"This study confirms the validity of calprotectin in distinguishing IBD from both IBS and control subjects and again illustrates that calprotectin levels are within the normal range in IBS," the researchers write.
While some IBD patients might technically qualify for an IBS diagnosis as well, the presence of IBS-like symptoms should always be interpreted as subclinical activity of their primary disease, according to the investigators.
Their conclusion: "Bottom line, IBD is IBD unless proven otherwise!"